Incidence of Side-Effects of Ticlopidine After Sirolimus-Eluting Stent Implantation Retrospective Analysis From Three Hospitals

Kenichi Fukushima; Yoshio Kobayashi; Tomonobu Okuno; Yoshitake Nakamura; Masayoshi Sakakibara; Takashi Nakayama; Nakabumi Kuroda; Akira Miyazaki; Youichi Shimizu; Issei Komuro

doi:10.1253/circj.71.617

Rapid Communication

Incidence of Side-Effects of Ticlopidine After Sirolimus-Eluting Stent Implantation

Retrospective Analysis From Three Hospitals

Kenichi Fukushima, Yoshio Kobayashi, Tomonobu Okuno, Yoshitake Nakamura, Masayoshi Sakakibara, Takashi Nakayama, Nakabumi Kuroda, Akira Miyazaki, Youichi Shimizu, Issei Komuro

著者情報

キーワード: Antiplatelet therapy, Stent, Stent thrombosis

ジャーナルフリー

2007 年 71 巻 4 号 p. 617-619

DOI https://doi.org/10.1253/circj.71.617

詳細

抄録

Background Because of its side-effects, long-term administration of ticlopidine limits the use of the sirolimus-eluting stent (SES) in Japan. Methods and Results Side-effects of ticlopidine occurred in 41 (9.3%) of 440 patients who underwent SES implantation. The majority were liver dysfunction (4.5%) and rash (3.6%). One patient died from severe liver dysfunction. Neutropenia occurred in 3 patients (0.7%). It is remarkable that 28% of side-effects occurred >8 weeks after the initiation of ticlopidine. Conclusions Ticlopidine has a relative high rate of side-effects. Clopidogrel should be approved for prevention of stent thrombosis as soon as possible. (Circ J 2007; 71: 617 - 619)

責任著者(Corresponding author)

J-STAGEへの登録はこちら（無料）